Diazepam metabolism by cDNA-expressed human 2C P450s: Identification of P4502C18 and P4502C19 as low K(M) diazepam N-demethylases

Drug Metabolism and Disposition

Volumn 25, Issue 2, 1997, Pages 133-139

  Jung, Frank ^b   Richardson, Toby H ^b   Raucy, Judy L ^b   Johnson, Eric F ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DIAZEPAM; KETOCONAZOLE; NORDAZEPAM; OXAZEPAM; TEMAZEPAM;

ARTICLE; CATALYSIS; CONTROLLED STUDY; DEMETHYLATION; DRUG HYDROXYLATION; DRUG METABOLISM; GENE EXPRESSION; HUMAN; HUMAN CELL; LIVER MICROSOME; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGED; ANTI-ANXIETY AGENTS; ARYL HYDROCARBON HYDROXYLASES; CHILD; CYTOCHROME P-450 ENZYME SYSTEM; DIAZEPAM; ESCHERICHIA COLI; FEMALE; HUMANS; ISOENZYMES; KETOCONAZOLE; KINETICS; MALE; MICROSOMES, LIVER; MIDDLE AGED; MIXED FUNCTION OXYGENASES; OXIDOREDUCTASES, N-DEMETHYLATING; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES;

ESCHERICHIA COLI;

EID: 0031034344     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. M. Mandelli, G. Tognoni, and S. Garattini: Clinical pharmacokinetics of diazepam. Clin. Pharmacokinet. 3, 72-91 (1978).
2. L. Bertilsson, T. K. Henthorn, E. Sanz, G. Tybring, J. Säwe, and T. Villén: Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin. Pharmacol. Ther. 45, 348-355 (1989).
3. M. L. Jack and W. A. Colburn: Pharmacokinetic model for diazepam and its major metabolite desmethyldiazepam following diazepam administration. J. Pharmaceut. Sci. 72, 1318-1323 (1983).
4. L. Bertilsson, T. A. Baillie, and J. Reviriego: Factors influencing the metabolism of diazepam. Pharmacol. Ther. 45, 85-91 (1990).
5. D. J. Greenblatt, M. Divoll, D. R. Abernethy, H. R. Ochs, and R. I. Shader: Benzodiazepine kinetics: implications for therapeutics and pharmacogeriatrics. Drug Metab. Rev. 14, 251-292 (1983).
6. D. J. Greenblatt, J. S. Harmatz, and R. I. Shader: Factors influencing diazepam pharmacokinetics: age, sex, and liver disease. Int. J. Clin. Pharmacol. Biopharm. 16, 177-179 (1978).
7. E. E. Ohnhaus, B. K. Park, J. P. Colombo, and P. Heizmann: The effect of enzyme induction on diazepam metabolism in man. Br. J. Clin. Pharmacol. 8, 557-563 (1979).
8. E. E. Ohnhaus, N. Brockmeyer, P. Dylewicz, and H. Habicht: The effect of antipyrine and rifampin on the metabolism of diazepam. Clin. Pharmacol. Ther. 42, 148-156 (1987).
9. U. Klotz and I. Reimann: Delayed clearance of diazepam due to cimetidine. N. Engl. J. Med. 302, 1012-1014 (1980).
10. D.-R. Sohn, M. Kusaka, T. Ishizaki, S.-G. Shin, I.-J. Jang, J.-G Shin, and K. Chiba: Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clin. Pharmacol. Ther. 52, 160-169 (1992).
11. T. Yasumori, K. Nagata, S. K. Yang, L. S. Chen, N. Murayama, Y. Yamazoe, and R. Kato: Cytochrome P450 mediated metabolism of diazepam in human and rat: involvement of human CYP2C in N-demethylation in the substrate concentration-dependent manner. Pharmacogenetics 3, 291-301 (1993).
12. m diazepam N-demethylase in livers of poor metabolizers for S-mephenytoin 4′-hydroxylation. Pharmacogenetics 4, 323-331 (1994).
13. J. A. Goldstein and S. M. de Morais: Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4, 285-299 (1994).
14. T. H. Richardson and E. F. Johnson: The cytochrome P4502C subfamily. In "Cytochromes P450: Metabolic and Toxicological Aspects" (C. Ionnides, ed.), pp. 161-181. CRC Press, Boca Raton, FL, 1996.
15. S. A. Wrighton, J. C. Stevens, G. W. Becker, and M. Vandenbranden: Isolation and characterization of human liver cytochrome P450 2C19: Correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch. Biochem. Biophys. 306, 240-245 (1993).
16. J. A. Goldstein, M. B. Faletto, M. Romkes-Sparks, T. Sullivan, S. Kitareewan, J. L. Raucy, J. M. Lasker, and B. I. Ghanayem: Evidence that CYP2C19 is the major (5)-mephenytoin 4′-hydroxylase in humans. Biochemistry 33, 1743-1752 (1994).
17. T. H. Richardson, F. Jung, K. J. Griffin, M. Wester, J. L. Raucy, B. Kemper, L. M. Bornheim, C. Hassett, C. J. Omiecinski, and E. F. Johnson: Universal approach to the expression of human and rabbit cytochrome P450s of the 2C subfamily in Escherichia coli. Arch. Biochem. Biophys. 323, 87-96 (1995).
18. J. L. Raucy and J. M. Lasker: Isolation of P450 enzymes from human liver. Methods Enzymol. 206, 577-587 (1991).
19. S. T. Okino, L. C. Quattrochi, U. R. Pendurthi, O. W. McBride, and R. H. Tukey: Characterization of multiple human cytochrome P-450 1 cDNAs. The chromosomal localization of the gene and evidence for alternate RNA splicing. J. Biol. Chem. 262, 16072-16079 (1987).
20. M. Romkes, M. B. Faletto, J. A. Blaisdell, J. L. Raucy, and J. A. Goldstein: Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry 30, 3247-3255 (1991).
21. Y. Yasukochi and B. S. S. Masters: Some properties of a detergent-solubilized NADPH-cytochrome c (cytochrome P-450) reductase purified by biospecific affinity chromatography. J. Biol. Chem. 251, 5337-5344 (1976).
22. E. F. Johnson, G. E. Schwab, and U. Muller-Eberhard: Multiple forms of cytochrome P-450: catalytic differences by two homogeneous forms of rabbit cytochrome P-450. Mol. Pharmacol. 15, 708-717 (1979).
23. P. E. B. Reilly, D. A. Thompson, S. R. Mason, and W. D. Hooper: Cytochrome P450IIIA enzymes in rat liver microsomes: involvement in C3-hydroxylation of diazepam and nordazepam but not N-dealkylation of diazepam and temazepam. Mol. Pharmacol. 37, 767-774 (1990).
24. J. L. Raucy, J. M. Lasker, C. S. Lieber, and M. Black: Acetaminophen activation by human liver cytochromes P450IIE1 and P450IA2. Arch. Biochem. Biophys. 271, 270-283 (1989).
25. S. J. Baldwin, J. C. Bloomer, G. J. Smith, A. D. Ayrton, S. E. Clarke, and R. J. Chenery: Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25, 261-270 (1995).
26. T. Omura and R. Sato: The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J. Biol. Chem. 239, 2370-2378 (1964).
27. H. H. Zhou, L. B. Anthony, A. J. J. Wood, and G. R. Wilkinson: Induction of polymorphic 4′-hydroxylation of S-mephenytoin by rifampicin. Br. J. Clin. Pharmacol. 30, 471-475 (1990).
28. T. Inaba, M. Jurima, W. A. Mahon, and W. Kalow: In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase. Drug Metab. Dispos. 13, 443-448 (1985).
29. S. D. Hall, F. P. Guengerich, R. A. Branch, and G. R. Wilkinson: Characterization and inhibition of mephenytoin 4-hydroxylase activity in human liver microsomes. J. Pharmacol. Exp. Ther. 240, 216-222 (1987).
30. T. Andersson, J. O. Miners, M. E. Veronese, and D. J. Birkett: Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. Br. J. Clin. Pharmacol. 38, 131-137 (1994).
31. J. O. Miners, K. J. Smith, R. A. Robson, M. E. McManus, M. Veronese, and D. J. Birkett: Tolbutamide hydroxylation by human liver microsomes. Biochem. Pharmacol. 37, 1137-1144 (1988).
32. L. S. Kaminsky, S. M. F. De Morais, M. B. Faletto, D. A Dunbar, and J. A. Goldstein: Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe. Mol. Pharmacol. 43, 234-239 (1993).
33. L. Pichard, R. Curi-Pedrosa, C. Bonfils, E. Jacqz-Aigrain, J. Domergue, H. Joyeux, J. Cosme, F. P. Guengerich, and P. Maurel: Oxidative metabolism of lansoprazole by human liver cytochromes P450. Mol. Pharmacol. 47, 410-418 (1995).
34. H. Furuya, U. A. Meyer, H. V. Gelboin, and F. J. Gonzalez: Polymerase chain reaction-directed identification, cloning, and quantification of human CYP2C18 mRNA. Mol. Pharmacol. 40, 375-382 (1991).